Abstract
Background SARS-CoV-2 is primarily transmitted through aerosolized droplets; however, the virus can remain transiently viable on surfaces.
Objective We examined transmission within hemodialysis facilities, with a specific focus on the possibility of indirect patient-to-patient transmission through shared dialysis chairs.
Design We used real-world data from hemodialysis patients treated between February 1st and June 8th, 2020 to perform a case-control study matching each SARS-CoV-2 positive patient (case) to a non-SARS-CoV-2 patient (control) in the same dialysis shift and traced back 14 days to capture possible exposure from chairs sat in by SARS-CoV-2 patients. Cases and controls were matched on age, sex, race, facility, shift date, and treatment count.
Setting 2,600 hemodialysis facilities in the United States.
Patients Adult (age ≥18 years) hemodialysis patients.
Measurements Conditional logistic regression models tested whether chair exposure after a positive patient conferred a higher risk of SARS-CoV-2 infection to the immediate subsequent patient.
Results Among 170,234 hemodialysis patients, 4,782 (2.8%) tested positive for SARS-CoV-2 (mean age 64 years, 44% female). Most facilities (68.5%) had 0 to 1 positive SARS-CoV-2 patient. We matched 2,379 SARS-CoV-2 positive cases to 2,379 non-SARS-CoV-2 controls; 1.30% (95%CI 0.90%, 1.87%) of cases and 1.39% (95%CI 0.97%, 1.97%) of controls were exposed to a chair previously sat in by a shedding SARS-CoV-2 patient. Transmission risk among cases was not significantly different from controls (OR=0.94; 95%CI 0.57 to 1.54; p=0.80). Results remained consistent in adjusted and sensitivity analyses.
Limitation Analysis used real-world data that could contain errors and only considered vertical transmission associated with shared use of dialysis chairs by symptomatic patients.
Conclusions The risk of indirect patient-to-patient transmission of SARS-CoV-2 infection from dialysis chairs appears to be low.
Primary Funding Source Fresenius Medical Care North America; National Institute of Diabetes and Digestive and Kidney Diseases (R01DK130067)
Competing Interest Statement
Ravi Thadhani is employed by Partners HealthCare. Joanna Willetts, John Larkin, Len Usvyat, Kathleen Belmonte, Robert Kossmann, Jeffrey Hymes, and Franklin Maddux are employees of Fresenius Medical Care. Hanjie Zhang, Lemuel Rivera Fuentes, Peter Kotanko are employees of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. Ravi Thadhani is a consultant for Fresenius Medical Care, Biogen Idec, Pfizer, Shire Human Genetics, and Celgene. Ravi Thadhani receives honoraria from Roche Diagnostics and ZS Pharma. Ravi Thadhani has ownership interests in Aggamin LLC. Len Usvyat, Kathleen Belmonte, Robert Kossmann, Jeffrey Hymes, Peter Kotanko, and Franklin Maddux have share options/ownership in Fresenius Medical Care. Ravi Thadhani receives research funding from the National Institutes of Health, Kaneka Corp, Diasorin, and ThermoFisher. Yuedong Wang receives research funding from the National Institutes of Health and Fresenius Medical Care. Ravi Thadhani has patents and invention interests that include ThermoFisher and Up-To-Date. Peter Kotanko is inventor on multiple patents in the field of dialysis. Ravi Thadhani is a scientific advisor for Aggamin LLC. Franklin Maddux has directorships in Fresenius Medical Care Management Board, Goldfinch Bio, and Vifor Fresenius Medical Care Renal Pharma. Peter Kotanko is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research.
Funding Statement
The analysis and manuscript were supported by Fresenius Medical Care North America. The analysis was also supported in part by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK130067.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient data were de-identified for analysis, which was performed under a regulatory protocol reviewed by New England Institutional Review Board (Needham Heights, MA, United States; NEIRB WO#: 17-1349084-1); the analysis was approved under Exempt Category (45 CFR 46.104-d4ii) and consent was not required. Analysis was conducted in adherence with Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This analysis was conducted on a deidentified dataset created by Fresenius Medical Care North America. This dataset is restricted to use under a formal collaboration agreement between Fresenius Medical Care North America and the investigators' institutions. The deidentified dataset is not publicly available.
